Clinical review report : Ranolazine (Corzyna) : (KYE Pharmaceuticals Inc.) : indication: stable angina pectoris, adults / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

CADTH common drug review

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Physical Description:

1 online resource.

Edition:

Version: Final.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2021.

Summary:

The objective of this report is to perform a systematic review of the beneficial and harmful effects of ranolazine 500 mg and 1,000 mg ER tablets as an add-on therapy for the treatment of stable angina pectoris in adults who are inadequately controlled or intolerant to first-line antianginal therapies.

Contents:

Abbreviations

Executive Summary

Introduction

Stakeholder Engagement

Clinical Evidence

Conclusions

Disease Background

Standards of Therapy

Drug

Patient Group Input

Clinician Input

Systematic Review (Pivotal and Protocol-Selected Studies)

Findings From the Literature

Results

Other Studies Included in the Systematic Review

Indirect Evidence

Other Relevant Evidence

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Literature Search Strategy

Appendix 2. Excluded Studies

Appendix 3. Detailed Outcome Data

Appendix 4. Description and Appraisal of Outcome Measures

References.

Notes:

Description based on publisher supplied metadata and other sources.